Inclusion Criteria:  Confirmed diagnosis of SPG11 Written signed informed consent  Exclusion Criteria:  Diagnosis of other concomitant neurodegenerative diseases taking other experimental drugs within 30 days of the first Study visit (T0) and during the study Refusal to sign informed consent